Pipeline

A growing pipeline of innovative cardiovascular & ophthalmology programs

Programs*

Pre-Clinical

Phase 1

Phase 2

Phase 3

Approval

Cardiovascular

Aficamten
(formerly CK274)
(cardiac myosin inhibitor)

oHCM

Ph 1 On-Going
Joining Global Ph3 in Q2 2022
Ph2 REDWOOD-HCM (Topline Results released)

nHCM / HFpEF

To be initiated
To be Initiated in early 2022

Etripamil Nasal Spray

PSVT

Initiate Ph3 and parallel PK Study by 2H 2022
Ph3 completion in Q3 2022

(short-acting calcium channel blocker)

Atrial fibrillation

To be initiated
Ph2 Initiated in Q2 2021

Ophthalmology

OC-01 Nasal Spray
(nAChR agonist in preservative-free formulation)

Dry eye disease

Initiate Ph3 and parallel Ph1 Study in 2H 2022
NDA submitted

OC-02 Nasal Spray
(nAChR agonist)

Dry eye disease

Initiate Ph3 and parallel Ph1 Study in 1H 2024
Ph2b Studies Completed

* Ji Xing has exclusive Greater China rights.

China studies conducted by Ji Xing
Global studies conducted by partner

Source: Cytokinetics, Milestone Pharmaceuticals, Oyster Point Pharma, Clinicaltrials.gov.
Note: oHCM = obstructive hypertrophic cardiomyopathy, nHCM = non-obstructive hypertrophic cardiomyopathy, HFpEF = heart failure with preserved ejection fraction, PSVT = paroxysmal supraventricular tachycardia.

Scroll to Top